Seeking Alpha

Chimerix anti-infection drug falls short in Phase II

  • Chimerix's (CMRX, -3.3%) CMX001 preemptive therapy for adenovirus (AdV) infection failed to achieve statistical significance in a Phase II trial of recipients of blood or bone marrow from donors.
  • However, Chimerix says that encouraging results from the first proof-of-concept study for adenovirus infection support the continued clinical development of CMX001.
  • AdV causes respiratory infections such as the common cold in healthy individuals. In patients with weakened immune systems, such as those who have recently received bone marrow or organ transplants, AdV infections have a high mortality rate. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: